Dana Investment Advisors Inc. Sells 13,875 Shares of Lantheus Holdings, Inc. $LNTH

Dana Investment Advisors Inc. decreased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 69.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,044 shares of the medical equipment provider’s stock after selling 13,875 shares during the period. Dana Investment Advisors Inc.’s holdings in Lantheus were worth $310,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of LNTH. Hantz Financial Services Inc. grew its stake in Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new position in shares of Lantheus in the second quarter worth $26,000. First Horizon Corp purchased a new position in shares of Lantheus in the third quarter valued at $26,000. Osterweis Capital Management Inc. bought a new stake in shares of Lantheus during the 2nd quarter valued at $36,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new stake in Lantheus during the 3rd quarter worth about $59,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Mizuho lifted their target price on Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a report on Friday. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Tuesday. Citizens Jmp upped their target price on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a report on Tuesday. William Blair upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday. Finally, Truist Financial set a $89.00 price target on shares of Lantheus in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $82.17.

Lantheus Trading Down 0.7%

Shares of Lantheus stock opened at $74.91 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $111.29. The firm has a market cap of $4.97 billion, a PE ratio of 22.23 and a beta of -0.08. The company has a 50 day simple moving average of $68.15 and a two-hundred day simple moving average of $60.14.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.37%. The company had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. During the same period in the previous year, the firm posted $1.59 EPS. The firm’s revenue was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Key Headlines Impacting Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.